Clinical trials: HBP
Hypertension
TARGET BP I Clinical Trial
The TARGET BP I Trial is a randomized, blinded, multi-center, international, sham-procedure controlled trial, comparing renal denervation performed with the Peregrine System Kit in the treatment group to the sham control group…
- Trial name
- TARGET BP I (NCT02910414)
- Testing
- Dehydrated alcohol
- Where
- 5 sites in United States
- Volunteers
- 300 people
- Sponsor
- Ablative Solutions, Inc.
Hypertension
Olmesartan Pediatric Pharmacokinetic (PK) Study
Determine single dose pharmacokinetic parameters of olmesartan in pediatric patients with hypertension in ages 12 months - 16 years
- Trial name
- NCT00151814
- Testing
- Olmesartan medoxomil
- Where
- 5 sites in United States
- Volunteers
- 24 people
- Sponsor
- Daiichi Sankyo
Ocular Hypertension, Primary Open-Angle Glaucoma
Safety and Efficacy of AGN-210961 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
This study has 2 parts. Part 1 will evaluate the safety and IOP effects of 6 formulations of AGN-210961 ophthalmic solution in the study eye and bimatoprost ophthalmic solution 0.03% in the fellow eye for 7 consecutive days.
- Trial name
- NCT01110499
- Testing
- AGN-210961 Formulation 1, AGN-210961 Formulation 2, AGN-210961 Formulation 3
- Where
- United States
- Volunteers
- 163 people
- Sponsor
- Allergan
Open-angle Glaucoma or Ocular Hypertension
Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension
The purpose of this study is to investigate the safety and efficacy of four concentrations of DE-117 ophthalmic solution.
- Trial name
- NCT01868126
- Testing
- DE-117 ophthalmic solution, latanoprost ophthalmic solution
- Where
- 7 sites in United States
- Volunteers
- 91 people
- Sponsor
- Santen Inc.
Glaucoma, Ocular Hypertension
Multiple Dose-parallel-group Study of AMA0076 in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension
The objective of this parallel group study is to evaluate the safety, tolerability and efficacy of AMA0076 in reduction of intraocular pressure in subjects with primary open-angle glaucoma or ocular hypertension.
- Conditions
- Glaucoma, Ocular Hypertension, Eye Disease
- Trial name
- NCT02136940
- Testing
- AMA0076
- Where
- 9 sites in United States
- Volunteers
- 103 people
- Sponsor
- Amakem, NV
Chronic Kidney Disease
Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria
This is a randomized, double-blind (DB), placebo controlled, crossover study with a two-period, two-sequence (2x2) design evaluating the efficacy and safety of 25 mg QD lorundrostat (an aldosterone synthase inhibitor [ASI]) in…
- Trial name
- NCT06150924
- Where
- 44 sites in United States
- Volunteers
- 60 people
- Sponsor
- Mineralys Therapeutics Inc.
Idiopathic Intracranial Hypertension (IIH)
Stenting Of Symptomatic Cerebral siNus stenosIs With the laserCut Self-expanding SILANCE Stent
The objective of this clinical investigation is to evaluate and demonstrate the clinical benefit, performance, and safety of the SILANCE Stent, which is specifically designed for the treatment of patients with symptomatic sinus…
- Trial name
- SONIC (NCT07561268)
- Testing
- SILANCE Stent Implantation
- Volunteers
- 99 people
- Sponsor
- Acandis GmbH
Open Angle Glaucoma
Study of ANX007 in Participants With Primary Open-angle Glaucoma
This is a double-masked, randomized, sham-controlled study evaluating two dose levels of ANX007 vs sham, administered as repeat Intravitreal (IVT) injections in patients with Primary Open-angle Glaucoma.
- Trial name
- NCT04188015
- Testing
- 2.5mg ANX007, 5.0mg ANX007
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Annexon, Inc.
Hypertension, Overweight or Obesity
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
GZL1 is an independent study conducted under the GZPL master protocol. GZL1 will evaluate the efficacy and safety of orforglipron for treatment of hypertension in participants with obesity or overweight.
- Trial name
- NCT06948435
- Testing
- Orforglipron
- Where
- 99 sites in United States, Argentina and 9 more
- Volunteers
- 487 people
- Sponsor
- Eli Lilly and Company
Pulmonary Hypertension
Phase III Randomized Study of UT-15 in Patients With Primary Pulmonary Hypertension
OBJECTIVES: I. Determine the safety and efficacy of UT-15 in patients with severe symptomatic primary pulmonary hypertension.
- Trial name
- NCT00004497
- Testing
- UT-15
- Where
- 7 sites in United States
- Sponsor
- United Therapeutics
Uncontrolled Hypertension, Resistant Hypertension
A Study to Evaluate the Efficacy and Safety in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension
This is a Phase II, multicentre, randomised, double-blinded, placebo-controlled, parallel group study to evaluate the safety, and effect of low, middle and high dose of SAL0120 versus placebo, administered once daily (QD) orally…
- Trial name
- NCT07790120
- Testing
- SAL0120
- Where
- China
- Volunteers
- 256 people
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Open-angle Glaucoma, Ocular Hypertension
A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension
The purpose of this study is to determine whether a glaucoma therapy is safe and effective in treating patients with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT00287521
- Testing
- AL-37807 Ophthalmic Suspension, 1.0%, Latanoprost, 0.005% (Xalatan), AL-37807 Vehicle
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- Alcon Research
Hypertension, Hyperlipidemia
Clinical Efficacy and Safety Evaluation of Co-administered HGP0904, HGP0608 and HGP0816 in Patients With Hypertension and Dyslipidemia
A phase 3 study to evaluate efficacy and safety of Co-administered HGP0904, HGP0608 and HGP0816 in Patients with Hypertension and Dyslipidemia
- Trial name
- NCT02899455
- Testing
- HGP0904, HGP0608, HGP0816
- Where
- South Korea
- Volunteers
- 146 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Hypertension
Impact of MK-0954A on Uric Acid in the Management of Hypertension (MK-0954A-366)
This was a retrospective, chart review, observational study to assess the effect of MK-0954A (losartan potassium 50 mg + hydrochlorothiazide 12.5 mg [Hyzaar(R)]) treatment for a period of at least three months on serum uric acid…
- Trial name
- NCT01368185
- Volunteers
- 1,705 people
- Sponsor
- Organon and Co
Essential Hypertension, Primary Hypercholesterolemia
A Study to Evaluate the Efficacy and Safety of Co-administrated BR1018B and BR1018C
The purpose of this clinical trial is to evaluate the efficacy and safety of co-administrated BR1018B and BR1018C in patients with essential hypertension and primary hypercholesterolemia
- Trial name
- NCT06165250
- Testing
- BR1018A, BR1018A-1, BR1018B
- Where
- 2 sites in South Korea
- Volunteers
- 151 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension
A Clinical Trial to Evaluate the Pharmacokinetics and Safety of Fimasartan and Rosuvastatin in Healthy Male Subjects
The purpose of this study is to evaluate the pharmacokinetics and safety of Fimasartan and rosuvastatin when coadministered or administered alone as a single dose or as multiple doses to healthy male subjects.
- Trial name
- NCT02704702
- Testing
- Fimasartan, Rosuvastatin, Fimasartan + Rosuvastatin
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension
A Study of the Effect of Nebivolol to Evaluate Its Vasodilatory Effects in Hypertensive Patients
The study is designed to compare the effects of nebivolol (10, 20, 40mg/day) with another beta blocker, extended-release metoprolol, at a range of doses.
- Trial name
- NCT00648895
- Testing
- Nebivolol, Metoprolol ER (TM)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Forest Laboratories
Hypertension, MTHFR 677 CC or CT Genotype
China Stroke Primary Prevention Trial 2 for Participants With H-type Hypertension and MTHFR 677 CC/CT Genotype (CSPPT2-CC/CT)
This is a multi-center, randomized, double-blind, double-dummy, controlled clinical trial. This trial will include 32,000 Chinese men and women with hypertension (H-type hypertension), MTHFR 677 CC or CT genotype, elevated plasma…
- Conditions
- Hypertension, MTHFR 677 CC or CT Genotype, Elevated Plasma Homocysteine (Hcy≥10µmol/L), Insufficient Plasma Folate Levels (<12ng/mL)
- Trial name
- CSPPT2-CC/CT (NCT04974138)
- Testing
- Amlodipine besylate, Amlodipine besylate and folic acid
- Where
- 20 sites in China
- Volunteers
- 32,000 people
- Sponsor
- Shenzhen Ausa Pharmed Co.,Ltd
Hypertension
Study of Losartan in Pediatric Patients With Hypertension (MK-0954-337)
This study will explore the dose-response of losartan as well as the safety and tolerability in children from 6 months to 6 years of age.
- Trial name
- NCT00756938
- Testing
- losartan potassium
- Volunteers
- 101 people
- Sponsor
- Organon and Co
Hypertension, Hyperlipidemias
A Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of DWC202206 and DWC202207 in Patients With Concomitant Hypertension and Hyperlipidemia
This study aims to evaluate the efficacy and safety of co-administration of DWC202206 and DWC202207 in patients with concomitant hypertension and hyperlipidemia.
- Trial name
- NCT05643508
- Testing
- (D) DWC202206, (D) DWC202207, (P) DWC202206
- Where
- South Korea
- Volunteers
- 214 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.